drugset / Trial / NCT05913388
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Phase 2
Recruiting
92 enrolled
Providence Health & Services
Galecto Biotech AB · collabProvidence Cancer Center · collabProvidence Cancer Center, Earle A. Chiles Research Institute · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine the objective response of GB1211 and pembrolizumab versus pembrolizumab and placebo in patients with advance metastatic melanoma or head and neck squamous cell carcinoma.
Timeline
- Start
- 2024-02-29
- Primary completion
- 2028-02
- Completion
- 2030-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Selvigaltin | Small molecule | 100 mg | Oral |